Reprogramming of adult or neonic stem cells and methods of use

• US 20070025973A1
• Filed: 07/28/2006
• Published: 02/01/2007
• Est. Priority Date: 07/29/2005
• Status: Abandoned Application

• Current Assignee: Daniel Richard, Frederick Fitzsimmons
• Original Assignee: Daniel Richard, Frederick Fitzsimmons
• Inventors: Richard, Daniel, Fitzsimmons, Frederick
• Application Number:
  US11/495,965
• Publication Number:
  US 20070025973A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 35/545 Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
• CPC Class Codes: C12N 2506/00 Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
• CPC Class Codes: C12N 5/0696 Artificially induced pluripotent stem cells, e.g. iPS
• CPC Class Codes: C12N 5/16 Animal cells

Abstract

The present invention relates to methods of reprogramming adult stem cells or stem cells obtained from umbilical or placental cord blood or more preferably, the placeta or umbilical cord tissue itself or the amniotic fluid or amnion. The resulting stem cells and methods of using these stem cells represent additional aspects of the present invention. Stem cells according to the present invention, especially neonic stem cells (those obtained/reprogrammed from neonate stem cells), represent great potential in duplicating embryonic stem cell research without utilizing embryonic stems cells which have raised ethical and moral issues. The stem cells of the present invention which are reprogrammed are obtained from adults or from neonates without causing injury or death to a fetus in the case of embryonic stem cells and are non-controversial. In this sense, the present invention avoids many of the legal, ethical or moral considerations which have complicated the use of embryonic stem cells.

Claims

1. Reprogrammed stem cells obtained by exposing adult pluripotent stem or progenitor cells or pluripotent stem or progenitor cells obtained from placental or umbilical cord tissue or placental or umbilical cord blood or amniotic fluid or amnion exposed to

a. an effective amount of embryonic stem cell medium or

b. a denucleation procedure to remove nuclear DNA from said stem cell followed by introduction of nuclear material from a cell of a patient to be treated.

2. The reprogrammed stem cells of claim 1 wherein said introduction occurs by fusing a patient cell with a denucleated stem cell.

3. The reprogrammed stem cells of claim 1 obtained by exposing stem cells from umbilical cord tissue to a denucleation procedure followed by introducing nuclear material from a patient cell.

4. The reprogrammed stem cells of claim 1 obtained by exposing stem cells from umbilical cord or placental blood to a denucleation procedure followed by introducing nuclear material from an adult cell into said denucleated stem cell.

5. The reprogrammed stems cells of claim 1 obtained by exposing stem cells from amniotic fluid or amnion to a denucleation procedure followed by introducing nuclear material from an adult cell into said denucleated cell.

6. The reprogrammed stem cells of claim 1 wherein said embryonic stem cell medium is a minimum essential medium further comprising at least one growth factor, glucose, non-essential amino acids, insulin and transferrin.

7. The reprogrammed cells of claim 6 wherein said growth factor is fibroblast growth factor, transforming growth factor beta or mixtures thereof and said medium further comprises at least one additional component selected from the group consisting gamma amino butyric acid, pipecholic acid, lithium and mixtures thereof.

21. A method of treating a patient for a disease state or condition treatable with stem cells, said method comprising administering to said patient effective amounts of reprogrammed stem cells according to claim 1.

22. The method according to claim 21 wherein said disease state or condition is cancer.

23. The method according to claim 22 wherein said cancer is leukemia.

24. The method according to claim 21 wherein said disease state or condition is a neurodegenerative disorder, a brain or spinal cord injury or a neurological deficit.

25. The method according to claim 21 wherein said disease state or condition is Parkinson'"'"'s disease, Huntington'"'"'s disease, multiple sclerosis (MS), Alzheimer'"'"'s disease, Tay Sach'"'"'s disease, lysosomal storage disease, or a brain or spinal cord injury.

26. A method of effecting hematopoietic reconstitution in a patient in need thereof, comprising administering to said patient an effective amount of reprogrammed stem cells according to claim 1.

27. The method according to claim 26 wherein the patient has an HIV infection or AIDS.

8. A method of reprogramming stem cells to produce non-controversial stem cells said method comprising:

a. providing a sample comprising at least one stem cell obtained from an adult, from placental umbilical cord tissue or from umbilical cord or placental blood or from amniotic fluid or amnion tissue; and

b. exposing said sample to an effective amount of embryonic stem cell medium.

9. The method according to claim 8 wherein said sample in step a is obtained from placenta or umbilical cord tissue.

10. The method according to claim 8 wherein said sample in step a is obtained from umbilical cord or placental blood.

11. The method according to claim 8 wherein said sample in step a is obtained from amniotic fluid or amnion tissue.

12. The method according to claim 8 wherein said embryonic stem cell medium is a minimum essential medium further comprising at least one growth factor, glucose, non-essential amino acids, insulin and transferrin.

13. The method according to claim 12 wherein said growth factor is fibroblast growth factor, transforming growth factor beta or mixtures thereof and said medium further comprises at least one additional component selected from the group consisting gamma amino butyric acid, pipecholic acid, lithium and mixtures thereof.

14. The method according to claim 13 wherein said growth factor is a mixture of fibroblast growth factor and transforming growth factor beta.

17. The method according to claim 8 wherein said sample in step a is obtained from umbilical cord or placental blood.

18. The method according to claim 8 wherein said sample in step a is obtained from amniotic fluid or amnion tissue.

15. A method of reprogramming stem cells to produce non-controversial stem cells said method comprising:

a. providing a sample comprising at least one stem cell obtained from an adult, from placental or umbilical cord tissue or from umbilical cord or placental blood, or from amniotic fluid or amnion tissue;

b. denucleating said stem cell from step a; and

c. introducing DNA from a patient into said denucleated stem cell.

16. The method according to claim 15 wherein said sample in step a is obtained from placental or umbilical cord tissue.

19. The method according to claim 15 wherein said denucleating step occurs by centrifugation.

20. The method according to claim 15 wherein said DNA is introduced into said denucleated stem cell by fusion with a cell from a patient to be treated.